

Ngrazier 10615126

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 Derwent World Patents Index(R) web-based training during  
August  
NEWS 5 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 6 AUG 30 CA/CAPLUS - Increased access to 19th century research documents  
NEWS 7 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 8 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 18:15:36 ON 19 SEP 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:15:41 ON 19 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9  
 DICTIONARY FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005


Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
 for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>  
 Uploading C:\Program Files\Stnexp\Queries\10615126.str



```
chain nodes :
15 16 17 18 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
4-21 9-15 12-16 16-17 17-18
ring bonds :
1-2 1-6 2-3 2-11 3-4 3-14 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 12-13 13-14
exact/norm bonds :
9-15 12-16 16-17 17-18
exact bonds :
1-2 1-6 3-4 4-5 4-7 4-21 5-6 5-10 7-8 8-9 9-10
normalized bonds :
2-3 2-11 3-14 11-12 12-13 13-14
isolated ring systems :
```

Ngrazier 10615126

containing 1 :

G1: Cy, Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:Atom 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:16:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 885 TO ITERATE

100.0% PROCESSED 885 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 15916 TO 19484

PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:16:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 18198 TO ITERATE

100.0% PROCESSED 18198 ITERATIONS

277 ANSWERS

SEARCH TIME: 00.00.01

Ngrazier 10615126

L3 277 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 18:16:29 ON 19 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2005 VOL 143 ISS 13

FILE LAST UPDATED: 18 Sep 2005 (20050918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 5 L3

=> d ed abs ibib hitstr 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 18 Jan 2004  
 GI



AB Title compds. I [wherein A = CR<sub>6</sub>R<sub>7</sub>CR<sub>8</sub>R<sub>9</sub>, COCR<sub>10</sub>R<sub>11</sub>, or CR<sub>12</sub>=CR<sub>13</sub>; X and Y = independently H, F, Cl, Br, or alkyl; R<sub>1</sub> = alkyl, alkenyl, or (un)substituted benzyl; R<sub>2</sub> = (un)substituted (cyclo)alkyl(alkyl), alkenyl, alkynyl, (hetero)aryl(alkyl), or heterocycl(alkyl); R<sub>3</sub> = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocycl, or (hetero)aryl; R<sub>4</sub> = OH or NR<sub>14</sub>R<sub>15</sub>; R<sub>5</sub> = H, halo, OH, CN, or (un)substituted (cyclo)alkyl(oxy), alkenyl, alkynyl, (hetero)aryl(oxy), heterocycl(oxy), carbamoyl, sulfamoyl, acyl(oxy), etc.; R<sub>6</sub>-R<sub>9</sub> = independently H, alkyl, F, or OH; R<sub>10</sub> and R<sub>11</sub> = independently H or alkyl; R<sub>12</sub> and R<sub>13</sub> = independently H, F, or alkyl; R<sub>14</sub> and R<sub>15</sub> = independently H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as glucocorticoid receptor agonists (no data). For example, (3S,4aR,10aR)-3-bromo-4a-ethyl-7-hydroxy-3,4,4a,9,10,10a-hexahydro-1H-phenanthren-2-one (multi-step preparation given) was treated with NaOH in DMF and H<sub>2</sub>O followed by 0.2M HCl to give a 2:1 mixture of the 2-keto-3-hydroxy and 2-hydroxy-3-keto derivs. The 2-keto enriched compound (9:1 ratio of 2-keto to 3-keto derivative) was alkylated with propyne in THF using BuLi in hexane to afford II (25%). Bioassays for glucocorticoid receptor modulation and antiinflammatory response are described, but no specific data are provided. Thus, I and their pharmaceutical compns., salts, and prodrugs are useful in the treatment of certain inflammatory disorders, endocrine disorders, collagen diseases, dermatol. diseases, allergic states, ophthalmic diseases, respiratory diseases, hematol. disorders, neoplastic diseases, edematous states, and gastrointestinal diseases (no data).

ACCESSION NUMBER: 2004:41424 CAPLUS

DOCUMENT NUMBER: 140:111136

TITLE: Preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions

INVENTOR(S): Chantigny, Yves Andre; Kleinman, Edward Fox; Robinson, Ralph Pelton, Jr.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2004005229   | A1   | 20040115 | WO 2003-IB2941  | 20030625   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,<br>CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,<br>GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,<br>LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,<br>PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,<br>TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,<br>FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,<br>BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |          |                 |            |
| CA 2491994  | AA   | 20040115 | CA 2003-2491994 | 20030625   |
| EP 1521733  | A1   | 20050413 | EP 2003-740911  | 20030625   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  |      |          |                 |            |
| BR 2003012575   | A    | 20050503 | BR 2003-12575   | 20030625   |
| US 2004138262   | A1   | 20040715 | US 2003-615126  | 20030708   |
| PRIORITY APPLN. INFO.:  |      |          | US 2002-394425P | P 20020708 |
|   |      |          | WO 2003-IB2941  | W 20030625 |

OTHER SOURCE(S): MARPAT 140:111136


IT 645397-14-4P, (2R,3S,4AR,10aR)-4a-Ethyl-7-[[[(2-methylpyridin-3-yl)methyl]oxy]-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-15-5P, (2R,3S,4AR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-16-6P, (2R,3S,4AR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-4-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-17-7P, (2R,3S,4AR,10aR)-7-[[[(2,4-Dimethylpyridin-3-yl)methyl]oxy]-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-18-8P, (2R,3S,4AR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-19-9P, (2R,3S,4AR,10aR)-4a-Ethyl-7-[[[(6-methylpyridin-3-yl)methyl]oxy]-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-20-2P, (2R,3S,4AR,10aR)-7-[[[5-[(Diethylamino)methyl]-[1,2,4]oxadiazol-3-yl]methyl]oxy]-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-27-9P 645397-32-6P 645397-33-7P 645397-34-8P 645397-46-2P 645397-50-8P 645397-51-9P 645397-76-8P 645397-77-9P 645397-93-9P 645397-94-0P 645397-95-1P 645398-06-7P 645398-07-8P 645398-08-9P 645398-09-0P 645398-10-3P 645398-11-4P 645398-12-5P 645398-13-6P 645398-15-8P 645398-16-9P 645398-17-0P 645398-23-8P, (2R,3R,4AR,10aR)-4a-Ethyl-3-methyl-7-[[[(2-methylpyridin-3-yl)methyl]oxy]-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-26-1P, (2R,3R,4AR,10aR)-7-[[[5-[2-(Azetidin-1-yl)ethyl]-[1,2,4]oxadiazol-3-yl]methyl]oxy]-4a-ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-27-2P 645398-28-3P, (2R,3R,4AR,10aR)-7-[[[5-(2-Dimethylaminoethyl)-[1,2,4]oxadiazol-3-yl]methyl]oxy]-4a-ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(glucocorticoid receptor modulator; preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)

RN 645397-14-4 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-propynyl)-, (2R,3S,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-15-5 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,3S,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-16-6 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-17-7 CAPLUS

CN 2,3-Phenanthrenediol, 7-[(2,4-dimethyl-3-pyridinyl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 645397-18-8 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-19-9 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 645397-20-2 CAPLUS

CN 2,3-Phenanthrenediol, 7-[[5-[(diethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-27-9 CAPLUS

CN 2,3-Phenanthrenediol, 2-(3-chloro-5-fluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-32-6 CAPLUS

Ngrazier 10615126

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-33-7 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-7-(3-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-34-8 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-46-2 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-2-(4-fluorophenyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 645397-50-8 CAPLUS

CN 2,3-Phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-4a-(phenylmethyl)-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-51-9 CAPLUS

CN 2,3-Phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-4a-(phenylmethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-76-8 CAPLUS

CN 2,3-Phenanthrenediol, 2-(2,6-difluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-77-9 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-93-9 CAPLUS


CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-(1H-tetrazol-5-ylmethoxy)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-94-0 CAPLUS  
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[3-(1H-tetrazol-5-yl)propoxy]-, (2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-95-1 CAPLUS  
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[4-(1H-tetrazol-5-yl)butoxy]-, (2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-06-7 CAPLUS  
 CN 2,3-Phenanthrenediol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-07-8 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-  
[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-phenyl-,  
(2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-08-9 CAPLUS

CN 2,3-Phenanthrenediol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-  
yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-,  
(2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-09-0 CAPLUS


CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-  
phenyl-7-[[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-,  
(2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-10-3 CAPLUS  
 CN Acetamide, N-[[[3-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-11-4 CAPLUS  
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[[5-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-12-5 CAPLUS  
 CN Morpholine, 4-[[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-13-6 CAPLUS  
 CN Piperazine, 1-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]acetyl]-4-methyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-15-8 CAPLUS  
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[2-(4-morpholinyl)ethoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-16-9 CAPLUS  
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[2-(1-piperidinyl)ethoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 645398-17-0 CAPLUS  
 CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3-dihydroxy-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-23-8 CAPLUS  
 CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645398-26-1 CAPLUS  
 CN 2,3-Phenanthrenediol, 7-[[5-[2-(1-azetidiny)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-27-2 CAPLUS

CN Acetamide, N-[[[3-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-28-3 CAPLUS

CN 2,3-Phenanthrenediol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10615126

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 03 May 2002  
 GI



AB Title compds. [I; R1 = alkyl, trifluoroalkyl, C.tplbond.CMe, C.tplbond.CCl, C.tplbond.CCF3, CF3, etc.; R2 = alkyl, alkenyl, (substituted) Ph; R3 = alkyl, amino, aminoalkyl, heterocyclyl, heterocyclylalkyl; Q = (CH2)n; n= 1-3; with provisos], were prepared for treatment of obesity, diabetes, inflammation, anxiety, depression, and neurodegeneration (no data). Thus, ethanimidamide, N-hydroxy-2-[[4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl]oxy]- (preparation given) and NaH in THF were heated at 60° for 20 min. The solution was cooled to room temperature and ethyl-N,N-dimethylglycine was added. The resultant mixture was heated to reflux for 1 h to give 57% 2-phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, [2R-(2α,4α,10α)].

ACCESSION NUMBER: 2002:330268 CAPLUS  
 DOCUMENT NUMBER: 136:340682  
 TITLE: Preparation of oxadiazolylalkoxyoctahydrophenanthrenes as glucocorticoid receptor modulators  
 INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley P.; Robinson, Ralph Pelton  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Eur. Pat. Appl., 39 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| EP 1201660  | A1   | 20020502 | EP 2001-308789  | 20011016   |
| EP 1201660  | B1   | 20050831 |                 |            |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR |      |          |                 |            |
| CA 2360313  | AA   | 20020430 | CA 2001-2360313 | 20011026   |
| US 2004014741   | A1   | 20040122 | US 2001-12274   | 20011026   |
| US 6852719  | B2   | 20050208 |                 |            |
| JP 2002193955   | A2   | 20020710 | JP 2001-330283  | 20011029   |
| BR 2001004834   | A    | 20020820 | BR 2001-4834    | 20011029   |
| PRIORITY APPLN. INFO.:  |      |          | US 2000-244302P | P 20001030 |
| OTHER SOURCE(S): MARPAT 136:340682  |      |          |                 |            |
| IT 418771-78-5P 418771-80-9P 418771-83-2P   |      |          |                 |            |
| 418771-86-5P 418771-89-8P 418771-92-3P  |      |          |                 |            |

418771-94-5P 418771-97-8P 418772-00-6P  
 418772-03-9P 418772-05-1P 418772-08-4P  
 418772-10-8P 418772-12-0P 418772-13-1P  
 418772-14-2P 418772-15-3P 418772-17-5P  
 418772-18-6P 418772-19-7P 418772-20-0P  
 418772-21-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of oxadiazolylalkoxyoctahydrophenanthrenes as glucocorticoid  
 receptor modulators)

RN 418771-78-5 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418771-80-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418771-83-2 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-86-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-89-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[5-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-1,2,4-oxadiazol-3-yl]methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-92-3 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(1-azetidiny)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-94-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-97-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 418772-00-6 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-03-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-05-1 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[2-(1-azetidiny)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-08-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 418772-10-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-(trifluoromethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-12-0 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-13-1 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(1-azetidinyethyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-14-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-15-3 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(diethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-17-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-18-6 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-19-7 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-20-0 CAPLUS  
 CN 2-Phenanthrenol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 418772-21-1 CAPLUS  
CN 2-Phenanthrenol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 03 May 2002  
 GI



AB Title compds. [I; R1 = (trifluoromethyl)alkyl, CF3, C.tplbond.CMe, C.tplbond.CCl, C.tplbond.CCF3, CH2OA; A = (trifluoromethyl)alkyl; R2 = alkyl, alkenyl, (substituted) Ph; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, haloalkynyl; R4 = H, alkylamino, alkylhet; R3R4N = het; het = (substituted) 5-7 membered (unsatd.) heterocyclic ring containing 1-3 of N, O, S; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with 1-4 R7; R7 = (substituted) alkyl; with provisos], were prepared for treatment of obesity, diabetes, depression, anxiety, neurodegeneration, and inflammatory disease (no data). A solution of 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-ethyl-[2R-(2 $\alpha$ ,4 $\alpha$ ,10 $\alpha$ )] (preparation given), COCl2, and Et3N in THF was stirred at room temperature for 3 h; 1-(2-aminoethyl)pyrrolidine was added followed by stirring overnight to give 41% carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester.

ACCESSION NUMBER: 2002:330263 CAPLUS  
 DOCUMENT NUMBER: 136:340495  
 TITLE: Preparation of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators  
 INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Robinson, Ralph Pelton, Jr.  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Eur. Pat. Appl., 42 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| EP 1201649  | A1   | 20020502 | EP 2001-309064  | 20011025   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR |      |          |                 |            |
| JP 2002193911   | A2   | 20020710 | JP 2001-328050  | 20011025   |
| CA 2360308  | AA   | 20020428 | CA 2001-2360308 | 20011026   |
| US 2002107235   | A1   | 20020808 | US 2001-6215    | 20011026   |
| BR 2001004831   | A    | 20020820 | BR 2001-4831    | 20011026   |
| PRIORITY APPLN. INFO.:  |      |          | US 2000-243993P | P 20001028 |
| OTHER SOURCE(S): MARPAT 136:340495  |      |          |                 |            |
| IT 419534-56-8P 419534-58-0P 419534-66-0P   |      |          |                 |            |
| 419534-68-2P 419534-70-6P 419534-72-8P  |      |          |                 |            |
| 419534-77-3P 419534-78-4P 419534-81-9P  |      |          |                 |            |

419534-82-0P 419534-84-2P 419534-94-4P  
 419534-95-5P 419534-99-9P 419535-09-4P  
 419535-10-7P 419535-12-9P 419535-13-0P  
 419535-30-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of octahydrophenanthrenyl carbamates as glucocorticoid receptor  
 modulators)

RN 419534-56-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-  
 octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl  
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-58-0 CAPLUS

CN 1-Piperazinecarboxylic acid, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-  
 hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-66-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-68-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-hydroxyethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-70-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-(1-pyrrolidinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-72-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1-piperidinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-77-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-methyl-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-78-4 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-(1-piperidinyl)-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 419534-81-9 CAPLUS

CN 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic acid, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-82-0 CAPLUS

CN 3,6-Diazabicyclo[3.2.2]nonane-3-carboxylic acid, 6-methyl-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-84-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-2-carboxylic acid, octahydro-8-(hydroxymethyl)-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester, (8R,9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-94-4 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-(dimethylamino)-, (4bS,7R,8aR)-  
 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-95-5 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 3,5-dimethyl-, (4bS,7R,8aR)-  
 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-99-9 CAPLUS  
 CN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-methyl-,  
 (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419535-09-4 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-(dimethylamino)-2,2,6,6-tetramethyl-,  
 (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419535-10-7 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 2-[(dimethylamino)methyl]-,  
 (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419535-12-9 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 2-[(diethylamino)methyl]-,  
 (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419535-13-0 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 2-[2-(1-pyrrolidinyl)ethyl]-,  
 (4bS, 7R, 8aR) -4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 419535-30-1 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-(1-pyrrolidinylmethyl)-,  
 (4bR, 7R, 8aR) -4b-ethyl-4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-7-(1-  
 propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 11 May 2001

AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

ACCESSION NUMBER: 2001:338070 CAPLUS

DOCUMENT NUMBER: 134:336224

TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X

INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| EP 1097709  | A2   | 20010509 | EP 2000-309441  | 20001026   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO |      |          |                 |            |
| AU 776724   | B2   | 20040916 | AU 2000-66695   | 20001024   |
| ZA 2000006008   | A    | 20020426 | ZA 2000-6008    | 20001026   |
| US 6589947  | B1   | 20030708 | US 2000-696822  | 20001026   |
| CA 2325069  | AA   | 20010429 | CA 2000-2325069 | 20001027   |
| NZ 507825   | A    | 20041126 | NZ 2000-507825  | 20001027   |
| PRIORITY APPLN. INFO.:  |      |          | US 1999-162340P | P 19991029 |

OTHER SOURCE(S): MARPAT 134:336224

IT 305822-13-3 305822-14-4 305822-22-4

305822-23-5 305822-25-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)

RN 305822-13-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-14-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-22-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-23-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-25-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-

Ngrazier 10615126



(9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 10 Nov 2000  
 GI



AB Title compds. [e.g., I; D = CR7, CR7R16, N, NR7, O' E = C, CR6, N; F = CR4, CR4R5, O; R = XR1; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2, R3 = null when adjacent dashed line = bond; R4, R5 = H, cyano, alkyl, alkoxy, etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7, R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14, R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO; Z = (un)substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds] were prepared as glucocorticoid receptor modulators (no data). E.g., 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addition with Me vinyl ketone in the presence of (S)-(-)- $\alpha$ -methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetrahydrophenanthrenone derivative. E.g., demethylation of the methoxytetrahydrophenanthrenone with boron trichloride, reduction of the enone with lithium and ammonia, addition of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid derivative which is coupled with 4-(aminomethyl)pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

ACCESSION NUMBER: 2000:790448 CAPLUS  
 DOCUMENT NUMBER: 133:350060  
 TITLE: Preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors  
 INVENTOR(S): Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Swick, Andrew Gordon  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 279 pp.

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 PATENT INFORMATION: 2

| PATENT NO.  | KIND | DATE     | APPLICATION NO.   | DATE     |
|---|------|----------|-------------------|----------|
| WO 2000066522   | A1   | 20001109 | WO 2000-IB366     | 20000327 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |      |          |                   |          |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |          |                   |          |
| CA 2372173  | AA   | 20001109 | CA 2000-2372173   | 20000327 |
| BR 2000010138   | A    | 20020122 | BR 2000-10138     | 20000327 |
| EP 1175383  | A1   | 20020130 | EP 2000-911172    | 20000327 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO   |      |          |                   |          |
| TR 200103104  | T2   | 20020521 | TR 2001-200103104 | 20000327 |
| JP 2002543169   | T2   | 20021217 | JP 2000-615356    | 20000327 |
| EE 200100567  | A    | 20030217 | EE 2001-567       | 20000327 |
| NZ 514465   | A    | 20031128 | NZ 2000-514465    | 20000327 |
| AU 776608   | B2   | 20040916 | AU 2000-33165     | 20000327 |
| US 6380223  | B1   | 20020430 | US 2000-559384    | 20000427 |
| ZA 2001008846   | A    | 20021028 | ZA 2001-8846      | 20011026 |
| NO 2001005272   | A    | 20011228 | NO 2001-5272      | 20011029 |
| HR 2001000804   | A1   | 20021231 | HR 2001-804       | 20011030 |
| BG 106142   | A    | 20020531 | BG 2001-106142    | 20011123 |
| US 2002147336   | A1   | 20021010 | US 2002-80174     | 20020219 |
| US 6699893  | B2   | 20040302 |                   |          |
| US 2003199527   | A1   | 20031023 | US 2003-413879    | 20030415 |
| US 6777404  | B2   | 20040817 |                   |          |
| US 2004176595   | A1   | 20040909 | US 2003-721318    | 20031125 |
| PRIORITY APPLN. INFO.:  |      |          |                   |          |
| US 1999-132130P P 19990430  |      |          |                   |          |
| US 1999-162340P P 19991029  |      |          |                   |          |
| WO 2000-IB366 W 20000327  |      |          |                   |          |
| US 2000-559384 A3 20000427  |      |          |                   |          |
| US 2000-696822 A3 20001026  |      |          |                   |          |
| US 2002-80174 A1 20020219   |      |          |                   |          |

OTHER SOURCE(S): MARPAT 133:350060


IT 305830-24-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305830-24-4 CAPLUS

CN 2-Phenanthrenol, 7-[(2-chloro-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 305822-12-2P 305822-13-3P 305822-14-4P  
305822-15-5P 305822-16-6P 305822-17-7P  
305822-18-8P 305822-19-9P 305822-21-3P  
305822-22-4P 305822-23-5P 305822-24-6P  
305822-25-7P 305822-27-9P 305825-51-8P  
305825-55-2P 305825-60-9P 305825-61-0P  
305825-66-5P 305825-72-3P 305825-75-6P  
305825-76-7P 305826-00-0P 305826-06-6P  
305826-07-7P 305826-11-3P 305826-12-4P  
305826-18-0P 305826-20-4P 305826-21-5P  
305826-25-9P 305826-88-4P 305827-02-5P  
305827-09-2P 305827-10-5P 305827-46-7P  
305827-48-9P 305827-51-4P 305827-55-8P  
305827-70-7P 305827-72-9P 305827-82-1P  
305827-84-3P 305827-86-5P 305827-88-7P  
305827-90-1P 305828-01-7P 305828-05-1P  
305828-07-3P 305828-09-5P 305828-15-3P  
305828-17-5P 305828-23-3P 305828-25-5P  
305828-27-7P 305828-29-9P 305828-31-3P  
305828-32-4P 305828-39-1P 305828-40-4P  
305828-43-7P 305828-44-8P 305828-45-9P  
305828-46-0P 305828-47-1P 305828-48-2P  
305828-49-3P 305828-50-6P 305828-51-7P  
305828-52-8P 305828-53-9P 305828-54-0P  
305828-56-2P 305828-57-3P 305828-58-4P  
305828-59-5P 305828-60-8P 305828-62-0P  
305828-63-1P 305828-64-2P 305828-65-3P  
305828-66-4P 305828-67-5P 305828-69-7P  
305828-72-2P 305828-73-3P 305828-74-4P  
305828-75-5P 305828-76-6P 305828-77-7P  
305828-78-8P 305828-79-9P 305828-80-2P  
305828-81-3P 305828-82-4P 305828-83-5P  
305828-84-6P 305828-85-7P 305828-86-8P  
305828-87-9P 305828-88-0P 305828-89-1P  
305828-90-4P 305828-91-5P 305828-93-7P  
305828-94-8P 305828-95-9P 305828-96-0P  
305828-97-1P 305828-98-2P 305828-99-3P  
305829-00-9P 305829-01-0P 305829-02-1P  
305829-03-2P 305829-04-3P 305829-05-4P  
305829-06-5P 305829-07-6P 305829-08-7P  
305829-09-8P 305829-10-1P 305829-11-2P  
305829-13-4P 305829-14-5P 305829-15-6P  
305829-16-7P 305829-17-8P 305829-18-9P  
305829-23-6P 305829-24-7P 305829-25-8P  
305829-31-6P 305829-32-7P 305829-34-9P  
305829-35-0P 305829-36-1P 305829-37-2P  
305829-47-4P 305829-50-9P 305829-51-0P  
305829-52-1P 305829-53-2P 305829-54-3P  
305829-55-4P 305829-56-5P 305829-57-6P  
305829-58-7P 305829-59-8P 305829-60-1P

305829-65-6P 305829-66-7P 305829-67-8P  
 305829-68-9P 305829-69-0P 305829-70-3P  
 305829-71-4P 305829-72-5P 305829-73-6P  
 305829-74-7P 305829-75-8P 305829-76-9P  
 305829-77-0P 305829-78-1P 305829-79-2P  
 305829-81-6P 305829-82-7P 305829-83-8P  
 305829-84-9P 305829-85-0P 305829-86-1P  
 305829-88-3P 305829-89-4P 305829-90-7P  
 305829-91-8P 305829-92-9P 305829-94-1P  
 305829-97-4P 305830-00-6P 305830-01-7P  
 305830-02-8P 305830-03-9P 305830-04-0P  
 305830-05-1P 305830-21-1P 305830-22-2P  
 305830-37-9P 305830-47-1P 305830-54-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305822-12-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-13-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-14-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Ngrazier 10615126


Absolute stereochemistry.



RN 305822-15-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305822-16-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-17-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-18-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-19-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-21-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-22-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-23-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-24-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.




RN 305822-25-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-27-9 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-51-8 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 305825-55-2 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyrimidinylloxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-60-9 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-61-0 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, monohydrochloride, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 305825-66-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305825-72-3 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-(2,6-dimethyl-4-morpholinyl)pentyl]oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-75-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinyl)pentyl]oxy]-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-76-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[[5-(1-pyrrolidinyl)pentyl]oxy]-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-00-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methyl-1-butynyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-06-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-methylpropyl)-4a-

(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-07-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methylbutyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-11-3 CAPLUS

CN 2-Phenanthrenepropanol, 1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-α,α-dimethyl-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Ngrazier 10615126


RN 305826-12-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(4-methylpentyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-18-0 CAPLUS  
CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-20-4 CAPLUS  
CN 2-Phenanthrenol, 2-(3,3-dimethyl-1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-21-5 CAPLUS  
 CN 2-Phenanthrene-2-yl 1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-25-9 CAPLUS  
 CN 2-Phenanthrene-2-yl 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-88-4 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, (4bS,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-02-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, (4bS,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-09-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(dimethylamino)-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-10-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-acetyl-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-46-7 CAPLUS

CN Piperazine, 1-methyl-4-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-48-9 CAPLUS

CN Piperidine, 1-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]-4-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-51-4 CAPLUS

CN 2-Phenanthrenol, 7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 305827-55-8 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 305827-70-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyrimidinyl)oxy-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-72-9 CAPLUS


CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-82-1 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-84-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-86-5 CAPLUS  
 CN 2-Phenanthrenol, 7-[(4,6-dimethoxy-1,3,5-triazin-2-yl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-88-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-90-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-01-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-05-1 CAPLUS

CN 2-Phenanthrenol, 7-[(4-chloro-2-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-07-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]methoxy]-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-09-5 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-15-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methoxy-2-pyrimidinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-17-5 CAPLUS  
 CN Morpholine, 4-[[6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]-3-pyridinyl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-23-3 CAPLUS  
 CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-25-5 CAPLUS

CN Pyridine, 3,3'-[[ (2R,4aS,10aR) -1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-27-7 CAPLUS

CN Pyridine, 4,4'-[[ (2R,4aS,10aR) -1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-29-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aR,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-31-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-32-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-39-1 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-40-4 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-43-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[3-(1-pyrrolidinyl)pyrazinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-44-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)-4-pyrimidinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 305828-45-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)-2-pyridinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-46-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)pyrazinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-47-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-48-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[2-(1-piperazinyl)ethoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-49-3 CAPLUS

CN Piperazine, 1-acetyl-4-[2-[[ (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-50-6 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyrimidin-2-yl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-51-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-52-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. ✓




RN 305828-53-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-54-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-56-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-pentyl-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-57-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(5-pyrimidinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-58-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-59-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[2-(1-pyrrolidinyl)-4-pyridinyl]methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-60-8 CAPLUS

Ngrazier 10615126

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-  
[[6-(1-pyrrolidinyl)-3-pyridinyl]methoxy]-, (2R,4aR,10aR)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 305828-62-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-  
4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-63-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-  
4a-(phenylmethyl)-2-propyl-, hydrochloride, (2R,4aS,10aR)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305828-64-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-2,4a-dipropyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-65-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-7-(2-piperidinylmethoxy)-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-66-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[1-(4-pyridinyl)ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-67-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-pentyl-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-69-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-72-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinyloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-73-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyrimidinylloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 305828-74-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methylpyrazinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-75-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxalinyloxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-76-6 CAPLUS  
 CN 2-Phenanthrenol, 7-[(3,6-dimethylpyrazinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-77-7 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-  
 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-78-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-  
 pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 305828-79-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-  
 pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-80-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[[4-(trifluoromethyl)-2-pyrimidinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-81-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[4-(trifluoromethyl)-2-pyrimidinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-82-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-83-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR) - (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-84-6 CAPLUS  
 CN Pyridine, 3,3'-[[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis[6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-85-7 CAPLUS  
 CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 305828-86-8 CAPLUS

CN 2-Pyridinecarbonitrile, 6-[[[(4bS, 7R, 8aR)-4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-87-9 CAPLUS

CN 2-Phenanthrenol, 7-[(3-amino-4-methyl-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R, 4aS, 10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-88-0 CAPLUS

CN 2-Phenanthrenol, 7-[(3-amino-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-89-1 CAPLUS

CN 3-Pyridinecarbonitrile, 6-methyl-2-[[ (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-90-4 CAPLUS

CN 3-Pyridinecarbonitrile, 6-methyl-2-[[ (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 305828-91-5 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-93-7 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[[[4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)




RN 305828-94-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[[6-(trifluoromethyl)-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)




RN 305828-95-9 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-96-0 CAPLUS  
 CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-97-1 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-98-2 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 305828-99-3 CAPLUS  
 CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-[[ (4bS,7R,8aR) -4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy] - (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-00-9 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2,6-dichloro-4-pyrimidinyl)methoxy] - 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-01-0 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)methoxy] - 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-02-1 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-  
 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-03-2 CAPLUS  
 CN 2-Phenanthrenol, 7-[(6-chloro-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-  
 octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 305829-04-3 CAPLUS  
 CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-  
 hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-05-4 CAPLUS

CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-06-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-6-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-07-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-

propynyl)-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-08-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-09-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-10-1 CAPLUS

CN 2(1H)-Pyridinone, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 305829-11-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-13-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-methyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-14-5 CAPLUS

CN 2-Phenanthrenol, 7-[(4,6-dimethyl-2-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-15-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-16-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-17-8 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxalinyloxy)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-18-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-23-6 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-24-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxypropyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 305829-25-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methoxy-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-31-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(methoxymethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






Ngrazier 10615126

RN 305829-32-7 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-34-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-5-thiazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-35-0 CAPLUS

CN 2-Phenanthrenol, 7-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-36-1 CAPLUS


CN 2-Phenanthrenol, 7-[[5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-37-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxy-1-propynyl)-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-47-4 CAPLUS  
CN 2-Phenanthrenol, 2-(3,3-dimethylbutyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Ngrazier 10615126

RN 305829-50-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-phenylethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-51-0 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-52-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-53-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-54-3 CAPLUS

CN 2-Phenanthrenol, 2-(azidomethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-55-4 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2-pyridinylmethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-56-5 CAPLUS  
 CN Propanenitrile, 3-[[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-phenanthrenyl]methoxy]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-57-6 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopentyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-58-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[[[(3-methyl-3-oxetanyl)methoxy]methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-59-8 CAPLUS

CN 2-Phenanthrenol, 2-[(1,1-dimethylethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-60-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(phenoxymethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-65-6 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[2-(2-pyridinyl)ethyl]-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-66-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(methylthio)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-67-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclobutylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-68-9 CAPLUS  
 CN 2-Phenanthrenol, 2-[(2-fluoroethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-

Ngrazier 10615126

4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-69-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[[2-(methylthio)ethoxy]methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-70-3 CAPLUS

CN 2-Phenanthrenol, 2-[(2,2-dimethylpropoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 305829-71-4 CAPLUS



Ngrazier 10615126


CN 2-Phenanthrenol, 2-[(2-ethylbutoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-72-5 CAPLUS  
CN 2-Phenanthrenol, 2-[(2-butynyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-73-6 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclohexylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Ngrazier 10615126

RN 305829-74-7 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopentylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-75-8 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclobutylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-76-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[[[3-phenyl-1-propynyl)oxy]methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-77-0 CAPLUS

CN 2-Phenanthrenol, 2-[[[(3-fluoro-3-methyl-1-butynyl)oxy)methyl]-  
1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-,  
(2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-78-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(1H-imidazol-1-ylmethyl)-  
4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 305829-79-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-  
pyridinylmethoxy)-2-(1H-1,2,4-triazol-1-ylmethyl)-, (2R,4aS,10aR)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-81-6 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-82-7 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-83-8 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-84-9 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(pyrazinyloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-85-0 CAPLUS

CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-86-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[4bS,7R,8aR]-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-88-3 CAPLUS

CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-89-4 CAPLUS

CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-90-7 CAPLUS

CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-91-8 CAPLUS

CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-  
[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-92-9 CAPLUS

CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-  
hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 305829-94-1 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclobutyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-  
[(1-oxido-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-97-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[[2-(1H-pyrazol-1-yl)ethoxy]methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305830-00-6 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-01-7 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.




RN 305830-02-8 CAPLUS  
 CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-03-9 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305830-04-0 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-05-1 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-21-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-22-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

(2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-37-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-pentynyl)-4a-(phenylmethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-47-1 CAPLUS

CN 2-Phenanthrenol, 2-(1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-54-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 305822-69-9P 305823-16-9P 305823-19-2P  
 305823-20-5P 305823-24-9P 305823-25-0P  
 305823-27-2P 305823-28-3P 305823-29-4P  
 305823-30-7P 305823-32-9P 305823-33-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305822-69-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(4-morpholinyl)pentyl]oxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-16-9 CAPLUS

CN 4-Morpholinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-19-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(3-pyrazinyl-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-20-5 CAPLUS

CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-24-9 CAPLUS

CN 2-Phenanthrenol, 7-(1H-tetrazol-5-ylmethoxy)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-25-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-27-2 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-28-3 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-29-4 CAPLUS

CN 1,2,4-Oxadiazole-5(2H)-thione, 3-[[[4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-30-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-32-9 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-33-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[2-(4-morpholinyl)-4-pyrimidinyl]oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR) - (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



Ngrazier 10615126

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

25.15

186.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.65

-3.65

STN INTERNATIONAL LOGOFF AT 18:17:07 ON 19 SEP 2005

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 11 May 2001

AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

ACCESSION NUMBER: 2001:338070 CAPLUS

DOCUMENT NUMBER: 134:336224

TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X

INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| EP 1097709  | A2   | 20010509 | EP 2000-309441  | 20001026   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO |      |          |                 |            |
| AU 776724   | B2   | 20040916 | AU 2000-66695   | 20001024   |
| ZA 2000006008   | A    | 20020426 | ZA 2000-6008    | 20001026   |
| US 6589947  | B1   | 20030708 | US 2000-696822  | 20001026   |
| CA 2325069  | AA   | 20010429 | CA 2000-2325069 | 20001027   |
| NZ 507825   | A    | 20041126 | NZ 2000-507825  | 20001027   |
| PRIORITY APPLN. INFO.:  |      |          | US 1999-162340P | P 19991029 |

OTHER SOURCE(S): MARPAT 134:336224

IT 305822-13-3 305822-14-4 305822-22-4

305822-23-5 305822-25-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)

RN 305822-13-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Ngrazier 10615126

RN 305822-14-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-22-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-23-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-25-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.






L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-15-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-[(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-16-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 INDEX NAME)

Absolute stereochemistry.




RN 305822-21-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-22-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-23-5 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305822-17-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-18-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-19-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-24-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-25-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 305822-27-9 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-51-8 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-55-2 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyrimidinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-60-9 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305825-72-3 CAPLUS  
 CN 2-Phenanthrenol, 7-[[5-(2,6-dimethyl-4-morpholinyl)pentyl]oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-75-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinyl)pentyl]oxy]-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-76-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[[5-(1-pyrrolidinyl)pentyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Absolute stereochemistry.



RN 305825-61-0 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, monohydrochloride, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305825-66-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Absolute stereochemistry.




RN 305826-00-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methyl-1-butynyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-06-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-methylpropyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-07-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methylbutyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 305826-11-3 CAPLUS  
CN 2-Phenanthrene-10-yl 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy- $\alpha,\alpha$ -dimethyl-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-12-4 CAPLUS  
CN 2-Phenanthrene-10-yl 2-(4-methylpentynyl)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305826-25-9 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 4-(dimethylamino)-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-88-4 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 4-(dimethylamino)-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-02-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-methyl-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305826-18-0 CAPLUS  
CN 2-Phenanthrene-10-yl 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-20-4 CAPLUS  
CN 2-Phenanthrene-10-yl 2-(3,3-dimethyl-1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-21-5 CAPLUS  
CN 2-Phenanthrene-10-yl 2-(4-methylpentynyl)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-09-2 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-(dimethylamino)-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305827-10-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-acetyl-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-46-7 CAPLUS  
CN Piperazine, 1-methyl-4-[[[4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 305827-48-9 CAPLUS  
CN Piperidine, 1-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-51-4 CAPLUS  
CN 2-Phenanthrenol, 7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-55-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-84-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[(5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl)methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305827-86-5 CAPLUS  
CN 2-Phenanthrenol, 7-[(4,6-dimethoxy-1,3,5-triazin-2-yl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-88-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[(3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl)methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-70-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyrimidinyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305827-72-9 CAPLUS  
CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-82-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 305827-90-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-01-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(pyrazinyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-05-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(4-chloro-2-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-07-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([3-(1-piperidinyl)methyl]-1,2,4-oxadiazol-5-yl)methoxy-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-09-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-([3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-15-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([5-methoxy-2-pyrimidinyl]oxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-27-7 CAPLUS  
 CN 2-Phenanthrenol, 4,4'-([{(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-29-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinyl)oxy-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-31-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Absolute stereochemistry.


RN 305828-17-5 CAPLUS  
 CN Morpholine, 4-([6-([4bS,7R,8aR]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-23-3 CAPLUS  
 CN 2-Phenanthrenol, 7-([5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-25-5 CAPLUS  
 CN Pyridine, 3,3'-([{(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-32-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-39-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-(2-(4-morpholinyl)ethoxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-40-4 CAPLUS  
 CN 2-Phenanthrenol, 7-([2,6-dimethoxy-4-pyrimidinyl]oxy)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-43-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[3-(1-pyrrolidinyl)pyrazinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-44-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)-4-pyrimidinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-45-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)-2-pyridinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 305828-49-3 CAPLUS  
 CN Piperazine, 1-acetyl-4-[2-[[4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-50-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyrimidinyl)oxy]-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-51-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 305828-46-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)pyrazinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-47-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)pyrazinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-48-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-(1-piperazinyl)ethoxy)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-52-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-53-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-54-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-56-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-morpholinyl)ethoxy]-4a-pentyl-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-57-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(5-pyrimidinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-58-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-62-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-63-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-2-propyl-, hydrochloride, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305828-64-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-morpholinyl)ethoxy]-4a-pentyl-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 305828-59-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-([2-(1-pyrrolidinyl)-4-pyridinyl]methoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-60-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-([6-(1-pyrrolidinyl)-3-pyridinyl]methoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-65-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-7-(2-piperidinylmethoxy)-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-66-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[1-(4-pyridinyl)ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-67-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-morpholinyl)ethoxy]-4a-pentyl-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-69-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(4-pentyl-2-propyl-7-(4-pyridinylmethoxy))- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-72-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinylmethoxy)- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-73-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyrimidinylmethoxy)- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-77-7 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-78-8 CAPLUS  
 CN 2-Phenanthrenol, 7-[(6-methyl-2-pyridinylmethoxy)-4a-(phenylmethyl)-2-propyl]- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-79-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-pyridinylmethoxy)-4a-(phenylmethyl)-2-(1-propynyl)]- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-74-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methylpyrazinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-75-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxalinyloxy)-4a-(phenylmethyl)-2-(1-propynyl)]- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-76-6 CAPLUS  
 CN 2-Phenanthrenol, 7-[(3,6-dimethylpyrazinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-80-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[(4-(trifluoromethyl)-2-pyrimidinyl)oxy]- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-81-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(4-(trifluoromethyl)-2-pyrimidinyl)oxy]- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-82-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinylmethoxy)-4a-(phenylmethyl)-2-propyl]- (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-83-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-84-6 CAPLUS  
 CN Pyridine, 3,3'-[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxyethylene)]bis[6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-88-0 CAPLUS  
 CN 2-Phenanthrenol, 7-[(3-amino-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-89-1 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-methyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-90-4 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-methyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305828-85-7 CAPLUS  
 CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-86-8 CAPLUS  
 CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-87-9 CAPLUS  
 CN 2-Phenanthrenol, 7-[(3-amino-4-methyl-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-91-5 CAPLUS  
 CN 3-Pyridinecarbonitrile, 2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-93-7 CAPLUS  
 CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)




RN 305828-94-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[[(6-(trifluoromethyl)-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-95-9 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-96-0 CAPLUS  
CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-97-1 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-98-2 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-99-3 CAPLUS  
CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-00-9 CAPLUS  
CN 2-Phenanthrenol, 7-[(2,6-dichloro-4-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-01-0 CAPLUS  
CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-02-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-03-2 CAPLUS  
CN 2-Phenanthrenol, 7-[(6-chloro-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-04-3 CAPLUS  
CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-05-4 CAPLUS  
CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-06-5 CAPLUS


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-6-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-07-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-08-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-13-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-methyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-14-5 CAPLUS  
 CN 2-Phenanthrenol, 7-[[[(4,6-dimethyl-2-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-09-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-10-1 CAPLUS  
 CN 2-[[1H]-Pyridinone, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-11-2 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-15-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-16-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-17-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxaliny]methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-18-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
INDEX NAME)

Absolute stereochemistry.



RN 305829-23-6 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[[[4bS,7R,8aR]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-24-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxypropyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-32-7 CAPLUS  
CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-34-9 CAPLUS  
CN 2-Phenanthrenol, 7-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-35-0 CAPLUS  
CN 2-Phenanthrenol, 7-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-25-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methoxy-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-31-6 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(methoxymethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-36-1 CAPLUS  
CN 2-Phenanthrenol, 7-[[5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-37-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxy-1-propynyl)-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-47-4 CAPLUS  
CN 2-Phenanthrenol, 2-(3,3-dimethylbutyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-50-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-phenylethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-51-0 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-52-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2-pyridinylmethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-56-5 CAPLUS  
 CN Propanenitrile, 3-[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-phenanthrenyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-57-6 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopentylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-53-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-54-3 CAPLUS  
 CN 2-Phenanthrenol, 2-(azidomethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-55-4 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-58-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(3-methyl-3-oxetanyl)methoxy)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-59-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(1,1-dimethylethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-60-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(phenoxymethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-65-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[(2-pyridinyl)ethyl]-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-66-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(methylthio)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-67-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclobutyl)oxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-71-4 CAPLUS  
 CN 2-Phenanthrenol, 2-[(2-ethylbutoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-72-5 CAPLUS  
 CN 2-Phenanthrenol, 2-[(2-butyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-68-9 CAPLUS  
 CN 2-Phenanthrenol, 2-[(2-fluoroethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-69-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(2-(methylthio)ethoxy)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-70-3 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-73-6 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclohexylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-74-7 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopentylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-75-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclobutylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 305829-76-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[[3-phenyl-1-propynyl]oxy]methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-77-0 CAPLUS

CN 2-Phenanthrenol, 2-[[3-(3-fluoro-3-methyl-1-butynyl)oxy]methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-78-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(1H-imidazol-1-ylmethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[[5-methyl-3-isoxazolyl]methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-83-8 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-84-9 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(pyrazinyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-85-0 CAPLUS

CN 2-Phenanthrenol, 7-[[2-amino-6-methyl-4-pyrimidinyl]oxy]-2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 2921/09/2005


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 305829-79-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(1H-1,2,4-triazol-1-ylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-81-6 CAPLUS


CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-82-7 CAPLUS


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 305829-86-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl]oxy]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-88-3 CAPLUS

CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[[2-methyl-3-pyridinyl]methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-89-4 CAPLUS

CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-90-7 CAPLUS  
 CN 2-Phenanthrenol, 2-[(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-91-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305830-00-6 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305830-01-7 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-02-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-92-9 CAPLUS  
 CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-94-1 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclobutylloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(1-oxido-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-97-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[(2-(1H-pyrazol-1-yl)ethoxy)methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 305830-03-9 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-04-0 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-05-1 CAPLUS  
 CN 2-Phenanthrenol, 2-[(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 305830-21-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-22-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 305822-69-9P 305823-16-9P 305823-19-2P  
305823-20-5P 305823-24-9P 305823-25-0P  
305823-27-2P 305823-28-3P 305823-29-4P  
305823-30-7P 305823-32-9P 305823-33-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of nonracemic octahydrophenanthrene and other tricyclic deriva.  
as selective modulators of glucocorticoid receptors)  
RN 305822-69-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(4-morpholinyl)pentyl]oxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305823-16-9 CAPLUS  
CN 4-Morpholinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
RN 305830-37-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-pentynyl)-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305830-47-1 CAPLUS  
CN 2-Phenanthrenol, 2-(1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-54-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305823-19-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(3-pyrazinyl-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-20-5 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-24-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(1H-tetrazol-5-ylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305823-25-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-methyl-1-piperazinyl)ethoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-27-2 CAPLUS  
 CN 2-Phenanthrenol, 7-([5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305823-28-3 CAPLUS  
 CN 1,2,4-Oxadiazol-5(2H)-one, 3-([[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 305823-33-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([2-(4-morpholinyl)-4-pyrimidinyl]oxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305823-29-4 CAPLUS  
 CN 1,2,4-Oxadiazole-5(2H)-thione, 3-([[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-30-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-([5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-32-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinyl)oxy-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)